Skip to main content

Lack of standardized description of TRAb assays

Abstract

Anti-thyroid stimulating hormone (TSH) receptor antibodies (TRAb) exist as both stimulating and blocking antibodies. The current TRAb assays widely available to clinicians are receptor-binding assays. Bioassays that differentiate between stimulating and blocking TRAb are technically challenging and expensive. The terminology used to describe the different assays is confusing and a potential source of misinterpretation of TRAb results. In this article, we point out a typographical error in the 2011 American Thyroid Association and American Association of Clinical Endocrinologists’ Guidelines on Hyperthyroidism where the term thyroid stimulating immunoglobulin (TSI) instead of thyroid binding inhibition immunoglobulin (TBII) was used in the description of TRAb results, to highlight the need to harmonize the terminology of TRAb assays to improve patient care.

This is a preview of subscription content, access via your institution.

References

  1. R.S. Bahn Chair, H.B. Burch, D.S. Cooper, J.R. Garber, M.C. Greenlee, I. Klein, P. Laurberg, I.R. McDougall, V.M. Montori, S.A. Rivkees, D.S. Ross, J.A. Sosa, M.N. Stan, American Thyroid Association; American Association of Clinical Endocrinologists, Hyperthyroidism and other causes of thyrotoxicosis, management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21, 593–646 (2011)

    PubMed  Article  Google Scholar 

  2. A.K. Eckstein, M. Plicht, H. Lax, M. Neuhauser, K. Mann, S. Lederbogen, C. Heckmann, J. Esser, N.G. Morgenthaler, Thyrotropin receptor autoantibodies are independent risk factors for graves’ ophthalmopathy and help to predict severity and outcome of the disease. J. Clin. Endocrinol. Metab. 91, 3464–3470 (2006)

    PubMed  Article  CAS  Google Scholar 

  3. S.Q. Mehdi, S.S. Nussey, A radio-ligand receptor assay for the long-acting thyroid stimulator. Inhibition by the long-acting thyroid stimulator of the binding of radioiodinated thyroid-stimulating hormone to human thyroid membranes. Biochem. J. 145, 105–111 (1975)

    PubMed  CAS  Google Scholar 

  4. C. Massart, R. Sapin, J. Gibassier, A. Agin, M. d’Herbomez, Intermethod variability in TSH-receptor antibody measurement: implication for the diagnosis of Graves disease and for the follow-up of Graves ophthalmopathy. Clin. Chem. 55, 183–186 (2009)

    PubMed  Article  CAS  Google Scholar 

  5. N.G. Morgenthaler, S.C. Ho, W.B. Minich, Stimulating and blocking thyroid-stimulating hormone (TSH) receptor autoantibodies from patients with Graves’ disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity, and binding sites. J. Clin. Endocrinol. Metab. 92, 1058–1065 (2007)

    PubMed  Article  CAS  Google Scholar 

Download references

Conflict of interest

To the best of our knowledge, no conflict of interest, financial or other, exists.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Karen Tan.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Tan, K., Loh, T.P. & Sethi, S. Lack of standardized description of TRAb assays. Endocrine 43, 732–733 (2013). https://doi.org/10.1007/s12020-012-9834-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-012-9834-5

Keywords

  • Anti-TSH receptor antibody (TRAb)
  • Thyroid binding inhibitor immunoglobulin (TBII)
  • Thyroid stimulating immunoglobulin (TSI)
  • Thyroid blocking immunoglobulin (TBI)